Who
Kristin Stafford
Director
Company insider
Files Form 4 as: Director, NovoCure; EVP, Chief Financial Officer, Zymeworks.
In numbers
- Trades disclosed
- 19
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $110K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 9 May 2023
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Jun 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —11,610 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —16,999 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —16,999 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —11,610 at $0.00 | filing |
| 2 Jun 2026filed 3 Jun 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $46K2,945 at $15.77 | filing |
| 2 Jun 2026filed 3 Jun 2026 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $46K2,945 at $15.77 | filing |
| 6 Apr 2026filed 7 Apr 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —178,000 at $0.00 | filing |
| 6 Apr 2026filed 7 Apr 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —119,000 at $0.00 | filing |
| 6 Apr 2026filed 7 Apr 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 6 Apr 2026filed 7 Apr 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —178,000 at $0.00 | filing |
| 6 Apr 2026filed 7 Apr 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —119,000 at $0.00 | filing |
| 6 Apr 2026filed 7 Apr 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —16,697 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —11,215 at $0.00 | filing |
| 3 Jun 2025filed 4 Jun 2025 | NVCR NovoCureMedical Devices | SEC FORM 4 Sold | $17K999 at $17.28 | filing |
| 5 Jun 2024filed 6 Jun 2024 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —6,229 at $0.00 | filing |
| 5 Jun 2024filed 6 Jun 2024 | NVCR NovoCureMedical Devices | SEC FORM 4 Code A | —4,053 at $0.00 | filing |
| 9 May 2023filed 17 May 2023 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —15,873 at $0.00 | filing |
| 9 May 2023filed 11 May 2023 | NVCR NovoCureoption or derivative · Medical Devices | SEC FORM 4 Code A | —15,873 at $0.00 | filing |
News
Reviewing NeurAxis (NASDAQ:NRXS) & NovoCure (NASDAQ:NVCR)NVCR · tickerreport.com · 15 Oct 2026NovoCure (NASDAQ:NVCR) and Medline (NASDAQ:MDLN) Financial AnalysisNVCR · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name Kristin Stafford; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.